690 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Sava Infond d.o.o.

Sava Infond d.o.o. purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 690 shares of the biopharmaceutical company's stock, valued at approximately $492,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Intact Investment Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $356,000. Principal Financial Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock worth $181,961,000 after acquiring an additional 2,828 shares during the period. Golden State Equity Partners grew its stake in shares of Regeneron Pharmaceuticals by 1,479.1% in the 4th quarter. Golden State Equity Partners now owns 1,358 shares of the biopharmaceutical company's stock valued at $967,000 after buying an additional 1,272 shares during the period. Fagan Associates Inc. increased its stake in Regeneron Pharmaceuticals by 42.2% during the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after acquiring an additional 3,832 shares during the last quarter. Finally, ABC Arbitrage SA acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $1,510,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Up 0.3 %

NASDAQ:REGN traded up $1.90 on Tuesday, reaching $636.13. The stock had a trading volume of 199,305 shares, compared to its average volume of 673,139. The company has a market cap of $69.54 billion, a price-to-earnings ratio of 16.59, a P/E/G ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm's fifty day moving average is $682.93 and its two-hundred day moving average is $791.84. Regeneron Pharmaceuticals, Inc. has a 12-month low of $618.51 and a 12-month high of $1,211.20.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $11.86 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a yield of 0.55%. Regeneron Pharmaceuticals's payout ratio is currently 2.30%.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research analyst reports. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective for the company. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a research report on Monday. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating for the company in a report on Tuesday, February 4th. Robert W. Baird cut their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a report on Wednesday, February 5th. Finally, Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their target price for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.